Minimally Invasive Lung Cancer Surgery Growth Analysis Report, Forecast to 2029

The Minimally Invasive Lung Cancer Surgery holds nearly 10% of the US$ 12 Bn cancer surgery market in 2021.
The global Lung Cancer Surgery Market was valued at US$ 1.23 Bn in 2021 and is expected to reach US$ 1.98 Bn by 2029, finds Future Market Insights (FMI) in a recent market survey.
Lung cancer refers to the growth of abnormal cells in the lung tissue. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are the two major types of lung cancer. Treatment options for lung cancer usually includes various types of therapies such as chemotherapy, radiation therapy, immunotherapy, targeted drug therapy and surgery.
Attempts to cure the disease with surgery involve the removal of the tumour, the surrounding lung tissue, and lymph nodes in the tumour area. Surgery is considered the treatment of choice for localized cancer, including carcinoid tumours.
The rising level of air pollution in developing economies and the increasing research and development activities on cancer treatment are some of the major trends bolstering the market outlook. The National Cancer Institute, for example, has been significantly offering funds to promote new cancer treatment and improve patient care, which in turn, could boost the acceptance of lung cancer removal surgery globally.

Additionally, substantial investment in research laboratories, the surge in air pollution levels, increasing smoking habits coupled with favourable reimbursement policies, specifically in developed countries will strengthen the growth of the Minimally Invasive Lung Cancer Surgery. 2014-2021 Market Demand Outlook for Lung Cancer Surgery compared to 2022-2029 Forecast
Rising air pollution and people getting affected by it is one of the prime factor responsible for the growth of the Minimally Invasive Lung Cancer Surgery. As per the lung cancer research foundation, lung cancer is the main reason of cancer death across the world.

According to American Cancer Society, it is estimated that in 2022, around 236,740 adults in the U.S. will be diagnosed with lung cancer while there will be 130,180 cases of deaths due to the lung cancer in the same year. Smoking is the prominent risk factor for lung cancer and is responsible for 80% of lung cancer deaths. Non-smokers account for 20% of lung cancer deaths.

Exposure to radon gas is another risk factor for lung cancer. This indicates the burden of lung cancer in the region and this is resulting in the growth of the lung cancer surgery market as there is a high demand for cancer treatment in the U.S.

The demand for lung cancer surgery grew at a CAGR of 5.5% between 2014 and 2021 globally. The rise in cases of lung cancer expects to raise the demand for lung cancer surgery. Growing incidences of lung cancer are expected to favour the demand for lung cancer surgery devices, owing to the large patient pool and need for effective treatment. Lung cancer incidences are increasing rapidly with the increase in high smoking rate, environmental pollution, and work-place exposures in milling, construction and automobile repairs.

Similarly, cigarette smoking is also one of the most common and known factors for developing lung cancer. Men who smoke often have 23 times more chances to develop lung cancer compared to non-smokers. Non-smokers have 20 to 30% chances of developing lung cancer due to exposure to secondhand smoke at work and home.

The lung cancer surgery market is expected to grow in the future, as the emergence of the latest technologies in the medical sector and the introduction of technologically advanced surgical energy instruments are magnifying the demand of this market. Advanced endoscopic devices and surgical instruments have increased the device versatility, thus ease the use of it in complex cases, leading to increase in number of lung resection procedures. Technology transformation has led to a positive impact on the global lung cancer surgery market growth.

Considering this, FMI expects global lung cancer surgery to grow at a CAGR of 6.1% through 2029.

Which Factors Are Restraining the Demand for Lung Cancer Surgery?
Lung cancer surgeries such as lobectomy, wedge resection, and other procedures are very high-cost surgeries. Affordability of the endoscopy and video-assisted lung surgery procedures is a major problem for a huge chunk of the population in the region. This is due to the absence of health insurance and limited government support policies that cover video-assisted surgeries in developing countries such as South Africa, India, and China.

The absence of social health insurance together with the exclusionary provision of private health insurance schemes are other major factors limiting the lung cancer surgery market growth.

Furthermore, post-surgery infections and risks associated with lung surgery are also expected to hamper the growth of the lung cancer surgery market. Lung resection procedures are often associated with various post-surgery complications and infections in some patients. Air leak is the most common complication after the lung resection procedure. Around 15% to 20% of patients reported air leaks after lung resection surgery. Some of the other complications associated with lung resection surgery includes bacterial pneumonia, acute respiratory failure, pulmonary embolism, postoperative haemorrhage, comorbid cardiovascular conditions and other conditions. All these factors might results in restraining the demand for these procedures during the forecast period. Country-wise Insights
What Makes the U.S. a Large Market for Lung Cancer Surgery?
In 2021, the U.S. is expected to account for about 93.9% of the North American lung cancer surgery market due to ease in FDA clearance encouraging lung cancer surgery device manufacturers in the region. For endoscope medical devices, the FDA 510(k) premarket approval process is followed. The Food and Drug Administration (FDA) has provided a list of class II (special control) devices which were subjected to certain limitations and which are now exempted from premarket notification requirements as per the Food and Drug Administration Modernization Act of 1997 (known as Modernization Act).

As per the Modernization Act and the related exemptions, device manufacturers and developers are relieved from the need to submit premarket submissions. Thus, enabling FDA to redirect resources to more significant public health issues. This helps minimize the time taken for regulatory approvals. Thus, reducing costs significantly and propelling the growth of the thoracoscope, bronchoscope markets as well as boosting up the growth of the lung cancer surgery devices market in the U.S.

Why is Germany Considered a Lucrative Market for Lung Cancer Surgery?
Germany is expected to account for 24.2% of the European market by 2021. The country dominates the European market owing to the high prevalence of lung cancer in Germany.

As per World Health Organization and Globocan, a total of 64,804 individuals were identified to have lung cancer in Germany which is nearly 10% of the total 628,519 cancer cases in 2020. Lung cancer was ranked 3rd on basis of its incidence rates while it was considered the top most reason behind the deaths caused by cancer.

What are the Factors Fueling the Demand for Lung Cancer Surgery in China?
The market for lung cancer surgery in China is projected to grow at 7.8% CAGR in the East Asia region throughout the forecast period. The high prevalence of lung cancer among the older population led to increased demand for lung cancer surgeries in China. The rapid rise in China’s adult population suffering from lung cancer is anticipated to boost the growth of the country’s lung cancer surgery market. This is because a maximum number of people diagnosed with lung cancer are 65 years and older. A small number of people aged below 45 are diagnosed with lung cancer. According to the WHO, by 2040, the elder population is expected to grow by 28% in China.

As per Globocan, Lung cancer was ranked 1st when considering the number of new cases (incidence rate) and highest no of deaths (mortality rate) due to different types of cancer. Around 815,563 new cases of lung cancer were identified in 2020 in China, whereas 714,699 cases of deaths were reported due to the same.

How will the Lung Cancer Surgery Market expand across India?
Demand for lung cancer surgery in India is expected to rise at an impressive 6.8% CAGR over the forecast period. The Asian countries have the highest population suffering from Chronic obstructive pulmonary disease (COPD), thus the risk of developing lung cancer increases significantly in the region. The number of COPD cases in India was a shocking 55.3 million in 2016. The threat of lung cancer in patients with COPD is two- to fivefold more compared with smokers without COPD. COPD prevalence is rising at a very high rate which is expected to increase the risk of lung cancer and favour the growth of the lung cancer surgery market over the forecast period in India.

Moreover, as per report published by WHO, levels of ultra-fine particles of less than 2.5 microns are maximum in India, which led India to become 16th most polluted city of the world, among the 30 most polluted cities. Thus, a rise in air pollution is primarily driving the lung cancer rate, and hence the Indian market is expected to be impacted.

Category-wise Insights
Surgical Energy Instruments anticipated continuing Gaining Traction
Based on the product type, the surgical energy instruments segment hold the maximum share of 42.5% in 2021, expanding at 6.6% CAGR during the forecast period. Advanced surgical instruments have increased the device adaptability and ease of use in complex surgical procedures, which drives lung cancer surgical procedures. Furthermore, Technology transformation has supplemented the growth of the surgical energy instruments segment.

Why does lobectomy contribute the highest market share by application?
In terms of Application, the lobectomy segment accounted for 68.0% of the total market share in 2021. Growing acceptance of VATS lobectomy is expected to favour the demand for endoscopic surgery equipment and advanced energy equipment and drive the growth of the lobectomy segment.

Which End User will be Most Preferred?
By End Users, Hospitals hold over 78.8% of the market in 2021 and this trend is expected to continue during the forecast period as well. Competitive Landscape
Market players lay greater emphasis on collaboration and partnership activities with local and regional players to expand sales and after-sales services for lung cancer surgery devices.

Through partnerships and acquisitions with regional players and third party service vendors, manufacturers expand their presence and product availability on a global level which is anticipated to fuel the growth of the lung cancer surgery devices market. For instance:

In June 2021, Intuitive launches robotic-assisted surgical stapler SureForm.
In December 2020, Medtronic Private Limited launched the first 3-row Circular Stapler with varied height staples - EEA Circular Stapler with Tri-Staple Technology in India.
In April 2019, Johnson & Johnson completed the acquisition of Auris Health Inc. a robotic platform technology manufacturer.
In March 2019, Titan Medical collaborated with Teleflex Inc. for the development of robotic ligation technology.
Click For More Info: https://www.futuremarketinsights.com/reports/lung-cancer-surgery-market